CyberArk Named a Leader in 2023 Gartner Magic Quadrant for Privileged Access Management
11.9.2023 18:06:00 EEST | Business Wire | Press release
CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2023 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is recognized in this report for the fifth consecutive time. Additionally, CyberArk is the only vendor positioned as a Leader in both Gartner Magic Quadrant Privileged Access Management (PAM) and Access Management 2 reports.
The CyberArk Identity Security Platform enables organizations to secure all identities – including workforce, IT, developer and non-human – against cyber threats with intelligent privilege controls. With CyberArk, customers have a single, unified platform for identity security that delivers operational efficiencies and faster ROI. Core to the platform are PAM solutions that secure standing, just-in-time and zero standing privileged access across hybrid and multi-cloud environments, and that improve secrets management to significantly reduce the #1 source of cyber risk: credential theft.
“We are extremely proud to be named a Leader by Gartner again. We believe this recognition underscores our commitment and track record of delivering continuous innovation to meet the evolving needs of our customers,” said Matt Cohen, CEO, CyberArk. “In today’s business and threat environment, every identity is a target for attackers. This is why we continue to extend intelligent privilege controls to all identities – human and machine – while developing deep product integrations across our platform, giving security teams the operational control and visibility they need to secure identities across the enterprise.”
CyberArk believes its consistent recognition as a Leader is the result of its focus on core foundational elements, including:
- Continuous Innovation: CyberArk continues to build upon core strengths in PAM and innovation across its PAM as-a-Service and self-hosted offerings. CyberArk has extended intelligent privilege controls across the entire identity lifecycle, for all types of identities. Recent innovations address emerging use cases for secure, developer-friendly access to public cloud workloads and services. New capabilities include just-in-time privileged access management and low-code and no-code automation workflows that enable automated identity orchestration. CyberArk Secrets Management, an essential part of PAM, is differentiated in its ability to allow organizations to centrally secure, manage and rotate secrets used by the broadest range of application identities. Earlier this year, CyberArk announced expanded secrets management capabilities, new AI-powered policy creation automation for improved endpoint privilege security and the ability for PAM administrators to broker, record and protect native privileged sessions in one-click.
- Exceptional Customer Experience: Globally, CyberArk provides flexible, closely aligned sales, technical and deployment resources to help customers accelerate time to value. Over the past year, CyberArk introduced new training programs and updates to the CyberArk Blueprint for Identity Security Success, in addition to ongoing complimentary access to resources such as the CyberArk Technical Community and CyberArk Success Blog. According to Gartner Peer Insights™, CyberArk has a 91% “would recommend” rating.3
- High Performance and Delivery: CyberArk Security Services, together with its global partner network of channel, MSPs, global systems integrators and advisory firms, help many of the world’s largest enterprises design, deploy and optimize PAM and identity security programs. CyberArk continues to nurture strong and consistent growth among its partner community through expanded training and enablement programs. Now, more than ever, CyberArk’s global ecosystem of C3 Alliance technology partners is critical to helping security teams consolidate and maximize existing investments to mitigate emerging risks and address evolving identity security challenges.
To download a complimentary copy of the 2023 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2023-mq-pam
1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Felix Gaehtgens, James Hoover, Michael Kelley, Brian Guthrie, Abhyuday Data, 5 September 2023
2 – Gartner® Magic Quadrant for Access Management, by Henrique Teixeira, Abhyuday Data, Michael Kelley, James Hoover, Brian Guthrie, 1 November 2022
3 – Gartner Peer Insights™ (rating as of Aug. 30, 2023; based on past 12 months), https://www.gartner.com/reviews/market/privileged-access-management/vendor/cyberark
Gartner Disclaimers
GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant and Peer Insights are a registered trademark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
About CyberArk
CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, Twitter, Facebook or YouTube.
Copyright © 2023 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911021116/en/
Contact information
Media Contacts:
Carissa Ryan, CyberArk
Email: press@cyberark.com
Highwire PR
Email: cyberark@highwirepr.com
Investor Relations:
Erica Smith, CyberArk
Email: ir@cyberark.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
